A Combined Biomarker of Bright CD38 and MYC ≥55% Is Highly Predictive of Double-/Triple-Hit High-Grade B-Cell Lymphoma.
A Combined Biomarker of Bright CD38 and MYC ≥55% Is Highly Predictive of Double-/Triple-Hit High-Grade B-Cell Lymphoma.
复制标题
Bright CD38 和 MYC ≥55% 的组合生物标志物可高度预测双重/三重打击高级别 B 细胞淋巴瘤。
DOI：
10.1093/ajcp/aqac047
复制
发表时间：
2022
影响因子：
3.5
通讯作者：
Weina Chen
中科院分区：
文献类型：
--
作者：
Abdullah N. Alsuwaidan;P. Koduru;F. Fuda;Jesse Manuel Jaso;Mingyi Chen;F. Rosado;H. Luu;N. Sweed;Rolando García;Meggie E. Doucet;N. Desai;K. Kumar;F. Awan;P. Ramakrishnan Geethakumari;Weina Chen
目标
诊断MYC和BCL 2或BCL 6重排的高级别B细胞淋巴瘤（双重/三重打击淋巴瘤[DTHL]）似乎要求对所有大B细胞淋巴瘤（LBCL）进行荧光原位杂交（FISH）检测。由于DTHL的发病率较低，我们的目的是确定DTHL的流式细胞术（FC）和免疫组化（IHC）功能，可用于开发一个最佳的筛选策略。尚未对这种组合的FC-IHC方法进行研究。
方法
我们比较了40例DTHL和39例无MYC重排的弥漫性LBCL（DLBCL）的特征。
结果
FC检测的CD38亮表达（CD38bright）、高MYC表达（≥ 55%）和IHC检测的双表达表型与DTHL显著相关。FC和IHC联合检测CD38bright和/或MYC ≥ 55%对DTHL的预测优于FC和IHC单独检测。将FISH检测限制在约25%的LBCL（基于CD38亮和/或MYC ≥ 55%），将检测约95%的DTHL-BCL 2和约75%的DHL-BCL 6。
结论
我们的研究表明，新的生物标志物CD38bright和/或MYC ≥ 55%是DTHL的高度预测。了解这种筛查策略的优点和局限性将有助于制定合理的诊断工作流程，以提供高质量的患者护理。
OBJECTIVES
Diagnosis of high-grade B-cell lymphoma with MYC and BCL2 or BCL6 rearrangements (double-/triple-hit lymphoma [DTHL]) appears to mandate fluorescence in situ hybridization (FISH) testing for all large B-cell lymphoma (LBCL). Given the low incidence of DTHL, we aimed to identify flow cytometry (FC) and immunohistochemistry (IHC) features of DTHL that could be used to develop an optimal screening strategy. This combined FC-IHC approach has not yet been studied.
METHODS
We compared features of 40 cases of DTHL and 39 cases of diffuse LBCL (DLBCL) without MYC rearrangement.
RESULTS
Bright CD38 expression (CD38bright) by FC, high MYC expression (≥55%), and double-expressor phenotype by IHC were significantly associated with DTHL. The biomarker combining FC and IHC, CD38bright and/or MYC ≥55%, was superior to FC and IHC markers alone in predicting DTHL. Restricting FISH testing to approximately 25% of LBCL based on CD38brightand/or MYC ≥55% would detect approximately 95% of DTHL-BCL2 and approximately 75% of DHL-BCL6.
CONCLUSIONS
Our study demonstrated that the novel biomarker of CD38bright and/or MYC ≥55% is highly predictive of DTHL. Awareness of the advantages and limitations of this screening strategy would facilitate development of a rational diagnostic workflow to provide high-quality patient care.